Patents Assigned to Chemokine Therapeutics Corp.
  • CXCR4 antagonist treatment of hematopoietic cells
    Patent number: 7435718
    Abstract: In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat hematopoietic cells, such as progenitor or stem cells, to promote the rate of cellular multiplication, self-renewal, proliferation or expansion. CXCR4 antagonists may be used therapeutically to stimulate hematopoietic stem/progenitor cell multiplication/self-renewal.
    Type: Grant
    Filed: September 20, 2004
    Date of Patent: October 14, 2008
    Assignees: Chemokine Therapeutics Corp., The University of British Columbia
    Inventors: Christopher R. Tudan, Ahmed Merzouk, Lakhdar Arab, Geeta Saxena, Connie J. Eaves, Johanne Cashman, Mary A. Richter, legal representative, Michael Clark-Lewis, legal representative, Hassan Salari, Ian Clark-Lewis
  • Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
    Patent number: 7368425
    Abstract: The present disclosure teaches analogs of human chemokines and methods of using them in the prevention, treatment, and ameliorization of diseases that can benefit from therapeutic angiogenesis. The teachings are generally directed to compositions comprising SDF-1 mimetics, as well as methods that include the use of SDF-1 mimetics to induce neo-vessel formation. The disclosure also teaches articles of manufacture that can be useful in practicing the methods taught herein.
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: May 6, 2008
    Assignee: Chemokine Therapeutics Corp.
    Inventors: Ahmed Merzouk, Carolina Abramovich, Hassan Salari